Comments
Glenmark Pharmaceuticals today said it has received final approval from the US health regulator for anti—fungal ointment nystatin and triamcinolone acetonide.
Glenmark Pharmaceuticals USA has been granted final approval by the US Food & Drug Administration (USFDA) for the “nystatin and triamcinolone acetonide cream USP, 100,000 units/gram and 1 mg/g,” the company said in a BSE filing.
The product is the generic version of Mycolog—II cream of Declor Asset Corporation, it added.
According to IMS Health sales data for the 12 month period ending August 2016, Mycolog—II cream achieved annual sales of around USD 120.9 million, Glenmark said.
The company’s current portfolio consists of 111 products authorised for distribution in the US marketplace and 60 Abbreviated New Drug Applications (ANDA) pending approval with the USFDA.
Glenmark Pharmaceuticals was today trading at Rs 933.70 in the morning trade on the BSE, up 0.03 per cent.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.